Bridgeway Capital Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Bridgeway Capital Management’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-102,440	Closed	-$26.6K	–	1500
2023 Q1	$26.6K	Hold	102,440	–	–	﹤0.01%	1347
2022 Q4	$21.5K	Hold	102,440	–	–	﹤0.01%	1338
2022 Q3	$26K	Hold	102,440	–	–	﹤0.01%	1384
2022 Q2	$74K	Hold	102,440	–	–	﹤0.01%	1256
2022 Q1	$81K	Hold	102,440	–	–	﹤0.01%	1271
2021 Q4	$102K	Hold	102,440	–	–	﹤0.01%	1220
2021 Q3	$179K	Hold	102,440	–	–	﹤0.01%	1210
2021 Q2	$187K	Sell	102,440 -100,000	-49%	-$177K	﹤0.01%	1269
2021 Q1	$409K	Buy	202,440 +92,500	+84%	+$216K	0.01%	1148
2020 Q4	$236K	Sell	109,940 -22,600	-17%	-$53.3K	0.01%	1175
2020 Q3	$358K	Buy	132,540 +70,000	+112%	+$251K	0.01%	1003
2020 Q2	$246K	Buy	+62,540	New	+$120K	0.01%	1095
2018 Q4	–	Sell	-4,275	Closed	-$20K	–	1510
2018 Q3	$20K	Hold	4,275	–	–	﹤0.01%	1423
2018 Q2	$20K	Sell	4,275 -28,219	-87%	-$148K	﹤0.01%	1403
2018 Q1	$234K	Hold	32,494	–	–	﹤0.01%	1251
2017 Q4	$233K	Hold	32,494	–	–	﹤0.01%	1256
2017 Q3	$270K	Hold	32,494	–	–	﹤0.01%	1224
2017 Q2	$331K	Hold	32,494	–	–	﹤0.01%	1188
2017 Q1	$375K	Hold	32,494	–	–	﹤0.01%	1147
2016 Q4	$408K	Hold	32,494	–	–	0.01%	1148
2016 Q3	$595K	Hold	32,494	–	–	0.01%	1011
2016 Q2	$345K	Hold	32,494	–	–	0.01%	1188
2016 Q1	$614K	Hold	32,494	–	–	0.01%	962
2015 Q4	$864K	Hold	32,494	–	–	0.02%	822
2015 Q3	$1.48M	Hold	32,494	–	–	0.03%	582
2015 Q2	$1.05M	Hold	32,494	–	–	0.02%	772
2015 Q1	$1.03M	Sell	32,494 -4,595	-12%	-$156K	0.02%	777
2014 Q4	$1.4M	Buy	37,089 +12,500	+51%	+$344K	0.03%	656
2014 Q3	$649K	Hold	24,589	–	–	0.02%	956
2014 Q2	$728K	Buy	24,589 +790	+3%	+$25.5K	0.02%	915
2014 Q1	$881K	Buy	+23,799	New	+$903K	0.03%	806

Other funds holding NAVB

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PFO

Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Bridgeway Capital Management's NAVB Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2023, closing a stake of 102,440 shares — an estimated $26.6K sold.

Bridgeway Capital Management first reported a position in NAVB in Q1 2014 and held it in 31 quarters. The position peaked at $1.48M in Q3 2015. 23 funds tracked by Wall St. Rank hold NAVB as of Q2 2023.

Bridgeway Capital Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 102,440 Navidea Biopharmaceuticals Inc. shares in Q2 2023, an estimated $26.6K.
Bridgeway Capital Management first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2014 and held it in 31 quarters.
Bridgeway Capital Management's Navidea Biopharmaceuticals Inc. position peaked at $1.48M in Q3 2015.
23 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.